| 词条 | Inotek Pharmaceuticals |
| 释义 |
Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts focused on the discovery, development and commercialization of novel therapies to treat glaucoma and other serious diseases of the eye. The Company's lead product candidate, trabodenoson (formerly known as INO-8875), is being evaluated for the treatment of elevated intraocular pressure associated with primary open-angle glaucoma (POAG) and ocular hypertension (OHT). Trabodenoson has completed Phase 1, 2, and 3 clinical trials in subjects with OHT and POAG. Inotek is developing trabodenoson as a monotherapy delivered via eye drop, as well as a fixed-dose combination (FDC) with latanoprost, one of the leading current treatments for OHT and POAG.[1] References1. ^{{Cite news|url=http://www.inotekpharma.com/clinical-development/|title=Clinical Development - Inotek Pharmaceuticals|newspaper=Inotek Pharmaceuticals|language=en-US|access-date=2016-12-15}} {{med-company-stub}} 3 : Biotechnology companies of the United States|Companies based in Lexington, Massachusetts|Companies formerly listed on NASDAQ |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。